SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class C

GOOG is trending as discussions swirl around its AI capabilities, particularly the Gemini 3 model, and its potential impact on competitors like NVDA. The community is weighing whether GOOG is becoming the dominant AI player, with some citing its custom silicon and potential for monetization. There's also buzz about the stock's valuation and recent analyst commentary.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

GOOGL is trending as investors weigh its AI prospects following positive reviews of its Gemini 3 model and news of Berkshire Hathaway taking a stake. Community discussions highlight GOOGL's potential to challenge competitors like NVDA and OpenAI, with some seeing it as undervalued. Bullish sentiment centers around Google's diverse AI capabilities and potential for future growth in the tech sector.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

SanDisk is trending due to its impending addition to the S&P 500, driving significant after-hours movement and sparking debate about whether the inclusion was leaked beforehand. The community is actively discussing the potential for further gains, contrasting opinions on shorting the stock, and the impact of memory storage demand in the AI sector. Others are pondering if the stock is overvalued after its recent runup.

Target Corp. engages in the operation and ownership of general merchandise stores. It offers food and general merchandise, clothing and household goods, electronics, and toys. Its brands include A New Day, All in Motion, Art Class, Auden, AVA & VIV, Boots and Barkley, Brightroom, Bullseye's Playground, Casaluna, Cat & Jack, Cloud Island, Colsie, dealworthy, Embark, Everspring, Favorite Day, Figmint, Future Collective, Gigglescape, Good & Gather, Goodfellow & Co, Hearth & Hand with Magnolia, Heyday, Hyde & EEK! Boutique, JoyLab, Kindfull, Kona Sol, Made By Design, Market Pantry, Mondo Llama, More Than Magic, Opalhouse, Open Story, Original Use, Pillowfort, Project 62, Room Essentials, Shade & Shore, Smartly, Smith & Hawken, Sonia Kashuk, Spritz, Sun Squad, Threshold, Universal Thread, up&up, Wild Fable, Wondershop, Xhilaration, California Roots, Casa Cantina, The Collection, Headliner, Jingle & Mingle, Rosé Bae, Photograph, SunPop, and Wine Cube. The company was founded by George Draper Dayton in 1902 and is headquartered in Minneapolis, MN.

Target Corp

Target ($TGT) is trending as investors weigh its upcoming earnings report amid concerns about consumer spending and competition from other retailers. The community is split, with some anticipating a potential value play due to its discounted valuation and dividend yield, while others fear further downside based on recent performance and economic headwinds. Discussions also include Target's AI initiatives and potential as a buyout target.

Symbotic, Inc. is an automation technology company, which engages in a robotics and automation-based product movement technology platform. It focuses on developing, commercializing, and deploying innovative, end-to-end technology solutions for supply chain operations. It operates through the United States and Canada geographical segments. The company was founded by Richard B. Cohen on December 11, 2020 and is headquartered in Wilmington, MA.

Symbotic Inc - Ordinary Shares - Class A

Symbotic Inc 

Symbotic is trending following its Q3 earnings release, sparking mixed reactions in the community. While the company exceeded revenue expectations, some investors are wary of the outlook and valuation, given its reliance on Walmart, triggering profit-taking. However, long-term bulls remain confident in SYM's growth potential within the warehouse automation and robotics space.

Sigma Lithium Corp. engages in the producing of a lithium property. It focuses its project in Minas Gerais. The firm also plans to build a world-class commercial-scale lithium concentration plant. The company was founded on June 8, 2011 and is headquartered in Sao Paulo, Brazil.

Sigma Lithium Corporation

SGML is trending due to renewed interest in lithium stocks, fueled by supply concerns stemming from potential mining license issues in China and positive price forecasts. Community discussions revolve around whether recent gains are sustainable, with some citing short squeeze potential while others point to insider selling and caution against overvaluation. The broader lithium sector and SGML's production capacity are key factors in the ongoing debate.

Mawson Infrastructure Group, Inc. engages in the provision of digital asset infrastructure services. The company was founded on February 10, 2012 and is headquartered in Midland, PA.

Mawson Infrastructure Group Inc

MIGI is trending due to a reported Q3 revenue jump and shift towards AI/GPU compute hosting, sparking community interest in its potential as a digital infrastructure play. Discussions revolve around its low float, recent reverse split, and possible short squeeze, with some seeing significant upside based on assets and sector comparisons. Some investors believe that the company is undervalued, especially in light of the rise of Bitcoin and AI.

shark raptor rocket launcher

SRRL (shark raptor rocket launcher) is trending as social media buzz points to a potential surge, with community members expressing strong confidence. Conversations suggest growing interest and speculation about a possible pump, while some caution about ownership concentration.

Monad is a high-performance Layer 1 blockchain that processes 10,000 transactions per second with near-zero fees. The platform delivers high performance without compromising on security or decentralization, creating the infrastructure needed for complex applications that require high-frequency activity.  One of Monad’s key innovations lies in how it handles transaction processing. Instead of processing transactions one at a time like traditional blockchains, Monad processes multiple transactions simultaneously through parallel execution.   The system separates the agreement process from the execution process, allowing validators to first agree on which transactions to include and in what order, then having more time to execute those transactions without slowing down consensus. This approach, combined with a custom-built database called MonadDB, dramatically increases throughput while maintaining accuracy.  Monad also offers complete EVM compatibility, where applications built for Ethereum work on Monad without any code modifications, and users can connect with familiar wallets like MetaMask just as they would on Ethereum. Developers can immediately tap into Ethereum's established ecosystem of tools, libraries, and applications while benefitting from Monad’s performance improvements. The platform also runs on consumer-grade hardware rather than expensive specialized equipment, making it accessible for more people to participate in securing the network.  Monad has raised approximately 244 million dollars in total funding across multiple rounds. The company secured 19 million dollars in a seed round in February 2023 led by Dragonfly Capital, followed by a 225 million dollar Series A round in April 2024 led by Paradigm at a 3 billion dollar valuation. Other notable investors include Electric Capital, Greenoaks, Coinbase Ventures, and prominent angel investors such as Naval Ravikant.

Monad

Monad ($MON) is gaining attention as traders discuss its potential, comparing it to established players like Solana ($SOL) and Bitcoin ($BTC). Community members are actively debating potential price movements and whether the current activity is a pump or the formation of a stable base. Concerns about VC involvement and potential rugs are also circulating within the community.

Fluence Energy, Inc. engages in energy storage products and services, and artificial intelligence-enabled digital applications for renewables and storage. The company was founded on June 21, 2021, and is headquartered in Arlington, VA.

Fluence Energy Inc - Ordinary Shares - Class A

Fluence Energy is trending due to positive sentiment following their Q4 earnings report and subsequent FY26 guidance, with community members highlighting the increased backlog and revenue expectations. Discussions revolve around the company's position in the growing BESS (Battery Energy Storage System) market and potential for significant growth, especially with AI driving demand for more power. Some are speculating on a potential short squeeze and potential takeover by BlackRock.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

FY2025 EPS Estimate for Palisade Bio Increased by Analyst

Palisade Bio, Inc. (NASDAQ:PALI - Free Report) - Analysts at Brookline Capital Management upped their FY2025 earnings per share estimates for shares of Palisade Bio in a research note issued to...

Palisade Bio (NASDAQ:PALI) Announces Earnings Results, Misses Estimates By $0.06 EPS

Palisade Bio (NASDAQ:PALI - Get Free Report) issued its earnings results on Monday. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.32) by...

Here's Why Palisade Bio (PALI) Could be Great Choice for a Bottom Fisher

After losing some value lately, a hammer chart pattern has been formed for Palisade Bio (PALI), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

All You Need to Know About Palisade Bio (PALI) Rating Upgrade to Buy

Palisade Bio (PALI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Retail traders piled into Palisade Bio on Wednesday after the biotech company said it would raise approximately $120 million from an underwritten public offering.The stock soared 52.4% on Wednesday to close at $0.45, marking its best session in more than nine months, and gained another 9.5% in after-hours trading.Palisade will offer approximately 171.4 million shares of its common stock, or its equivalent, at $0.70 per share. The underwriters also have an option to purchase about 25.7 million shares at $0.70 for a period of 45 days. Ladenburg Thalmann &amp; Co. Inc. is leading the process, which is expected to close on October 2.The company further stated that the proceeds from the deal will be used to fund its drug pipeline, targeting autoimmune, inflammatory, and fibrotic conditions.The fresh fundraising follows a series of recent developments on the drug development front. Last month, Palisade reported positive early-stage data from its experimental drug PALI-2108 in the treatment of inflammatory bowel diseases. In a small ulcerative colitis trial, the treatment was found to improve outcomes for all patients, with two patients achieving complete remission. The drug was also found to be safe and well-tolerated in a prior study.Palisade also recently secured regulatory approval in Canada to commence an early-stage trial of PALI-2108 in fibrostenotic Crohn’s disease. The study is expected to kick off later this year and will deliver its first data in early 2026.On Stocktwits, retail sentiment for Palisade Bio was ‘extremely bullish’ amid a 33,300% surge in 24-hour message volume.One user stated that the stock appeared strong in overnight trading and expected it to reach $2 by Thursday. At the same time, another predicted that Palisade Bio could rally further next week following weekend data updates.<stembedurl>https://stocktwits.com/Tazdoc88/message/630728209</stembedurl><stembedurl>https://stocktwits.com/smolcapcat/message/630723724</stembedurl><a href="https://stocktwits.com/symbol/PALI">Palisade Bio’s stock</a> has declined 20.6% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Palisade Bio’s stock (PALI) has declined 20.6% so far in 2025. (Photo credit: Getty Images)

Palisade Bio Stock Climbs To 9-Month High After $120M Stock Offering; Retail Sees More Gains Ahead

The rally came as traders reacted to its $120 million capital raise, aimed at accelerating development of new therapies for autoimmune, inflammatory, and fibrotic diseases.

Equity

Palisade Bio Announces 1-for-15 Reverse Stock Split

Carlsbad,CA, April 03, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), ( Palisade , Palisade Bio or the Company ), a biopharmaceutical company focused on developing and...

Palisade Bio files to sell 3.63M shares of common stock for holders

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Analysts Are Bullish on Top Healthcare Stocks: Inventiva (IVA), Palisade Bio (PALI)

Theres a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Inventiva (IVA Research Report) and Palisade Bio...

Palisade Bio Reports Year End 2023 Financial Results and Provides Corporate Update

Rapid advancement of PALI-2108 towards Phase 1 clinical study for the treatment of moderate-to-severe ulcerative colitis; On track to commence Phase 1 before year end Formation of Clinical...

Palisade Bio to Present at Digestive Disease Week (DDW) 2024

Carlsbad,CA, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) ( Palisade or the Company ), a biopharmaceutical company focused on developing novel therapeutics for...

This account has been verified as an official PALI representative.

Verified Account

Palisade Bio

Palisade Bio, Inc. is a biopharmaceutical company, which engages in the development of oral therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. It offers LB1148, an oral formulation of a broad-spectrum serine protease inhibitor designed to neutralize the activity of potent digestive proteases released from the gut during surgery. The company was founded on September 6, 2011 and is headquartered in Carlsbad, CA.

Palisade Bio Inc

Buying

Holding

Selling or trimming

Watching from the sidelines

What are you doing with Alphabet ($GOOGL) stock as it hits fresh all-time highs?

PALI
Palisade Bio Inc

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest PALI News

PALIPalisade Bio Inc